Liquidia Corp LQDA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:06 PM EDT
4.38quote price arrow down-0.10 (-2.23%)
Volume
155,335
52 week range
2.25 - 7.78
Loading...
  • Open4.53
  • Day High4.61
  • Day Low4.36
  • Prev Close4.48
  • 52 Week High7.78
  • 52 Week High Date04/06/22
  • 52 Week Low2.25
  • 52 Week Low Date08/06/21

Key Stats

  • Market Cap281.81M
  • Shares Out64.34M
  • 10 Day Average Volume1.46M
  • Dividend-
  • Dividend Yield-
  • Beta0.29
  • YTD % Change-8.83

KEY STATS

  • Open4.53
  • Day High4.61
  • Day Low4.36
  • Prev Close4.48
  • 52 Week High7.78
  • 52 Week High Date04/06/22
  • 52 Week Low2.25
  • 52 Week Low Date08/06/21
  • Market Cap281.81M
  • Shares Out64.34M
  • 10 Day Average Volume1.46M
  • Dividend-
  • Dividend Yield-
  • Beta0.29
  • YTD % Change-8.83

RATIOS/PROFITABILITY

  • EPS (TTM)-0.79
  • P/E (TTM)-5.52
  • Fwd P/E (NTM)-4.68
  • EBITDA (TTM)-36.561M
  • ROE (TTM)-69.89%
  • Revenue (TTM)13.26M
  • Gross Margin (TTM)77.20%
  • Net Margin (TTM)-311.71%
  • Debt To Equity (MRQ)36.21%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Liquidia Corp

There is no recent news for this security.

Profile

MORE
Liquidia Corporation is a biopharmaceutical company that is focused on the development, manufacturing and commercialization of products, which address unmet patient needs with a focus directed towards the treatment of pulmonary hypertension (PH). The Company operates, through its wholly owned subsidiaries, Liquidia Technologies and Liquidia PAH. Liquidia Technologies has developed YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension...
Stephen Bloch M.D.
Independent Chairman of the board
Roger Jeffs Ph.D.
Chief Executive Officer, Director
Robert Lippe
Chief Operations Officer
Michael Kaseta
Chief Financial Officer
Russell Schundler J.D.
General Counsel, Secretary
Address
419 Davis Drive, Suite 100, Suite
Morrisville, NC
27560
United States

Top Peers

SYMBOLLASTCHG%CHG
LCTX
Lineage Cell Therapeutics Inc
1.44-0.04-2.70%
FDMT
4D Molecular Therapeutics Inc
7.04UNCHUNCH
EIGR
Eiger BioPharmaceuticals Inc
6.09-0.34-5.29%
FULC
Fulcrum Therapeutics Inc
4.85-0.37-7.09%
RYTM
Rhythm Pharmaceuticals Inc
4.36-0.32-6.84%